Shingles vaccine linked to 24% lower dementia risk
Older adults who received the Shingrix shingles vaccine were 24% less likely to be diagnosed with dementia over four years in a study of more than 500,000 people. Researchers estimate the difference could amount to roughly one dementia case prevented for every 17 people vaccinate
The recent study linking the Shingrix shingles vaccine to a 24% lower dementia risk has significant implications for the fields of immunology and neurology. This finding suggests that the vaccine may have a previously unknown benefit, potentially offering a new avenue for dementia prevention. As researchers continue to unravel the complex causes of dementia, this discovery highlights the importance of exploring the intersection of infectious diseases and neurodegenerative disorders.
The Shingrix vaccine, developed by GlaxoSmithKline, was approved by the FDA in 2017 for the prevention of shingles, a painful rash caused by the varicella-zoster virus. The vaccine's success has been well-documented, with high efficacy rates against shingles and its complications. This new research adds another layer of value to the vaccine, potentially expanding its target population to include individuals at risk of dementia. Industry stakeholders will be watching closely as further studies validate these findings and explore the underlying mechanisms driving this association.
As researchers delve deeper into the relationship between the Shingrix vaccine and dementia risk, inventors and developers should take note of the potential for immunotherapies to influence neurodegenerative disease trajectories. With the global dementia market projected to grow exponentially in the coming years, innovations that can prevent or slow disease progression will be highly prized. Key areas to watch include the development of new vaccines or therapeutics that target viral infections and their links to neurodegenerative diseases, as well as investigations into the molecular mechanisms driving the observed association between Shingrix and dementia risk reduction.
Originally reported by sciencedaily.com. InventorsNews adds analysis for science & discovery readers.